TABLE 2.

Adverse events reported in at least 2 subjects

Adverse event	No. (%) of adverse eventsa
	Part C				Part D, 600 mg/day	Part E, 600 mg/day	Active total, n = 30
	Placebo	150 mg/day	300 mg/day	600 mg/day
Any adverse event	4 (67)	3 (50)	3 (50)	2 (33)	3 (50)	4 (67)	15 (50)
Abdominal pain, upper	1 (17)	1 (17)	1 (17)	0	0	0	2 (7)
Blood cholesterol increased	0	0	1 (17)	2 (33)	2 (33)	1 (17)	6 (20)
Blood glucose increased	0	1 (17)	0	0	1 (17)	0	2 (7)
Blood potassium increased	1 (17)	1 (17)	0	1 (17)	0	0	2 (7)
Blood triglycerides increased	0	1 (17)	2 (33)	1 (17)	1 (17)	1 (17)	6 (20)
Dyspepsia	1 (17)	0	0	0	1 (17)	0	1 (3)
Headache	1 (17)	2 (33)	0	0	0	0	2 (7)
Platelet count decreased	0	0	0	0	0	2 (33)	2 (7)

^aAll treatments except placebo were AT-527. For all treatment groups except total, n = 6.